INTELLIA THERAPEUTICS INC's ticker is NTLA and the CUSIP is 45826J105. A total of 263 filers reported holding INTELLIA THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 0.75 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $59,460,619 | -18.4% | 1,880,245 | +5.3% | 0.01% | -22.2% |
| Q2 2023 | $72,830,945 | +18.0% | 1,785,947 | +7.9% | 0.01% | +12.5% |
| Q1 2023 | $61,696,448 | +110986.7% | 1,655,391 | +4.0% | 0.01% | 0.0% |
| Q4 2022 | $55,539 | -99.9% | 1,591,847 | +15.8% | 0.01% | -33.3% |
| Q3 2022 | $76,896,000 | +14.9% | 1,374,128 | +6.3% | 0.01% | +20.0% |
| Q2 2022 | $66,904,000 | -25.0% | 1,292,588 | +5.4% | 0.01% | -9.1% |
| Q1 2022 | $89,153,000 | -38.8% | 1,226,824 | -0.5% | 0.01% | -38.9% |
| Q4 2021 | $145,729,000 | -9.3% | 1,232,492 | +3.0% | 0.02% | -18.2% |
| Q3 2021 | $160,589,000 | -11.3% | 1,197,090 | +7.0% | 0.02% | -12.0% |
| Q2 2021 | $181,141,000 | +121.1% | 1,118,780 | +9.6% | 0.02% | +92.3% |
| Q1 2021 | $81,943,000 | +74.7% | 1,021,038 | +18.4% | 0.01% | +62.5% |
| Q4 2020 | $46,910,000 | +218.3% | 862,342 | +16.3% | 0.01% | +166.7% |
| Q3 2020 | $14,739,000 | +7.0% | 741,436 | +13.1% | 0.00% | 0.0% |
| Q2 2020 | $13,775,000 | +90.6% | 655,355 | +10.9% | 0.00% | +50.0% |
| Q1 2020 | $7,228,000 | -55.1% | 591,041 | -46.1% | 0.00% | 0.0% |
| Q4 2019 | $16,094,000 | +109.3% | 1,097,126 | +90.4% | 0.00% | 0.0% |
| Q3 2019 | $7,691,000 | -6.8% | 576,118 | +14.3% | 0.00% | 0.0% |
| Q2 2019 | $8,251,000 | +20.1% | 504,085 | +25.3% | 0.00% | 0.0% |
| Q1 2019 | $6,872,000 | -30.0% | 402,359 | -44.0% | 0.00% | 0.0% |
| Q4 2018 | $9,812,000 | +0.3% | 718,958 | +110.4% | 0.00% | -33.3% |
| Q3 2018 | $9,779,000 | +36.4% | 341,708 | +30.4% | 0.00% | +50.0% |
| Q2 2018 | $7,170,000 | +70.2% | 262,085 | +31.2% | 0.00% | +100.0% |
| Q1 2018 | $4,213,000 | +11.9% | 199,790 | +2.0% | 0.00% | 0.0% |
| Q4 2017 | $3,765,000 | +10.2% | 195,925 | +42.5% | 0.00% | 0.0% |
| Q3 2017 | $3,417,000 | +128.3% | 137,514 | +46.9% | 0.00% | 0.0% |
| Q2 2017 | $1,497,000 | +39.6% | 93,603 | +23.0% | 0.00% | – |
| Q1 2017 | $1,072,000 | +13.9% | 76,095 | +6.0% | 0.00% | – |
| Q4 2016 | $941,000 | -19.5% | 71,804 | +4.5% | 0.00% | -100.0% |
| Q3 2016 | $1,169,000 | -18.6% | 68,703 | +2.0% | 0.00% | 0.0% |
| Q2 2016 | $1,437,000 | – | 67,346 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 1,216,340 | $62,958,000 | 7.04% |
| Discovery Value Fund | 584,483 | $30,253,000 | 6.33% |
| MPM BioImpact LLC | 299,409 | $15,497,000 | 4.30% |
| ARK Investment Management | 9,514,580 | $439,003,000 | 2.60% |
| Elmwood Wealth Management, Inc. | 67,899 | $3,514,000 | 2.00% |
| Nikko Asset Management Americas, Inc. | 2,781,136 | $141,143,000 | 1.74% |
| Avidity Partners Management LP | 1,125,194 | $58,240,000 | 1.34% |
| Merlin Capital, Inc | 12,174 | $630,000 | 1.26% |
| Atlas Venture Associates IX, LLC | 10,000 | $518,000 | 1.18% |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA | 111,440 | $5,768,000 | 1.16% |